Drug Development and Pharmacology Program

It is a big step from the laboratory to the bedside, particularly when it comes to the discovery and testing of new cancer-fighting treatments. The development of more effective chemotherapy treatment for pediatric cancers requires a better understanding of the pharmacology of anti-cancer agents and the means by which tumors develop drug resistance. Texas Children's Cancer Center has developed a comprehensive program of drug development and clinical and laboratory-based pharmacology that focuses on the preclinical study and clinical development of new agents to treat pediatric malignancies. The Drug Development and Clinical Pharmacology Program has achieved national recognition as a major center for the development of novel chemotherapy approaches to pediatric cancer treatment.

Texas Children's clinical pharmacologists have developed a number of new anti-cancer agents currently undergoing clinical trials within the Cancer Center. Many of the clinical trials performed at Texas Children's Cancer Center are supported in part by the hospital's National Institutes of Health-supported General Clinical Research Center (GCRC).

Texas Children's Cancer Center pharmacologists recently received a grant of nearly $1.5 million from the National Institute of Child Health and Human Development to fund the Texas Children's Pediatric Pharmacology Research Unit. This unit conducts studies to assure the safety of drug treatments in children.

Page modified on August 1, 2021